Tag: Radiopharmaceutical therapy
-
Fast SPECT Acquisitions Enable Single-Time-Point Dosimetry for 177Lu-PSMA in mCRPC Patients
Overview Single-time-point (STP) dosimetry has emerged as a practical alternative to traditional multi-time-point approaches for radiopharmaceutical therapies. In metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labelled PSMA (177Lu-PSMA), STP dosimetry at around 48 hours post-administration can reliably estimate absorbed doses to kidneys and tumors, reducing imaging burden and streamlining clinical workflows. Why STP Dosimetry…
-
Radiopharmaceutical Therapy Boosts Radiation, Slows Prostate Cancer
What the LUNAR trial tested SAN FRANCISCO, September 28, 2025 — A new phase II clinical trial, called LUNAR, shows that adding a radiopharmaceutical drug before high-precision radiation therapy can help people with a limited number of metastatic lesions from recurrent prostate cancer live longer without disease progression. In this randomized study, patients received either…
-
Radiopharmaceutical Therapy Boosts Radiation in Prostate Cancer
LUNAR Trial: Combining Radiopharmaceutical Therapy with SBRT A phase II study known as the LUNAR trial investigated whether adding a PSMA-targeted radiopharmaceutical before high-precision radiation could improve outcomes for men with oligometastatic, hormone-sensitive recurrent prostate cancer. In this randomized study, 92 participants with one to five distant lesions visible on PSMA PET/CT were assigned to…